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ABSTRACT
Spontaneous mutants resistant to fluoroquinolones were obtained by exposing Serratia marcescens NIMA
(wild-type strain) to increasing concentrations of ciprofloxacin both in liquid and on solid media. Frequen-
cies of mutation ranged from 10 2 7 to 10 2 9. Active expulsion of antibiotic was explored as a possible mecha-
nism of resistance in mutants as well as changes in topoisomerase target genes. The role of extrusion mecha-
nisms in determining the emergence of multidrug-resistant bacteria was also examined. Mutants resistant to
high concentrations of fluoroquinolones had a single mutation in their gyrA QRDR sequences, whereas the
moderate resistance in the rest of mutants was due to extrusion of the drug.
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INTRODUCTION
THE INTR ODU CTIO N O F FLU O RO QUINOLO NES more than 10years ago offered clinicians orally or parenterally admin-
istrable compounds with a broad spectrum of activity and ther-
apeutic results not seen before for a wide range of infections,
including complicated urinary-tract infections, gastrointestinal
infections, sexually transmitted diseases, respiratory-tract infec-
tions and chronic osteomyelitis. 2 Extensive use and misuse of
these compounds in both human and veterinary medicine led to
the emergence and spread of resistant clones.30 Widely varying
percentages of resistance to fluoroquinolones have been associ-
ated with particular bacterial species, clinical setting, origin of
strains, geographic locations and local antibiotic policies.6
Mutations in the structural genes encoding the target (DNA
gyrase and topoisomerase IV)34,35 and modifications in perme-
ability as result of decreased influx and/or increased efflux25
can lead to resistance to quinolones. In Gram-negative  bacteria
the outer membrane and their narrow porin channels limit the
penetration of hydrophilic solutes whereas the low fluidity of
the lipopolysaccharid e leaflet slows down the diffusion of hy-
drophobic solutes.27 However, the permeability barrier formed
by the outer membrane is not sufficient to confer clinically sig-
nificant levels of antibiotic resistance. Moreover, resistance is
often the result of the combination of several mechanisms. One
of these mechanisms is the extrusion of drugs by efflux
pumps.9,22 Active efflux proteins are common in wild-type bac-
teria, and contribute significantly to intrinsic resistance in
species such as Pseudomonas aeruginosa , Escherichia coli,
Haemophilus influenzae and others. The most frequent Mul-
tidrug resistance pumps of Gram-negative  bacteria are mem-
brane translocases that have the surprising ability to extrude a
variety of unrelated compounds from the cell in a proton-mo-
tive-force-depende nt manner, acting as a drug/H 1 antiporter
(Root Nodule Division (RND pumps)). The AcrAB system of
E. coli and the MexAB-OprM system of Pseudomonas aeru-
ginosa are the best known examples.21,28 Here we examine the
role of outer membrane permeability and extrusion mechanisms
of quinolone resistance in the opportunistic pathogen Serratia
marcescens .
MATERIALS AND METHODS
Media and chemicals
Trypticase Soy Broth (TSB) and Trypticase Soy Agar (TSA)
and Mueller Hinton broth (MH)] were purchased from Sharlau
(Barcelona, Spain). The antibiotics, ciprofloxacin and nalidixic
acid were kindly supplied by CENAVISA laboratories (Reus,
Spain). Chlorampheni col, tetracycline, kanamycin, eryth-
romycin, imipenem, crystal violet and acriflavine were pur-
chased from SIGMA.
Bacteria and culture conditions
S. marcescens NIMA37 was used as parental strain. Selec-
tion of quinolone-resista nt mutants was performed in liquid cul-
ture or on agar plates. For the selection in liquid culture (Ncip),
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10 m l of an overnight culture of the strain was diluted into 1
ml of TSB containing ciprofloxacin (0.06 m g/ml (MIC)) and
incubated overnight, then 10 m l of the culture was inoculated
to 1 ml of culture medium with 0.125 m g/ml (two fold MIC
value), again after incubation a new 10 fold dilution was made
in a medium containing four-fold MIC ciprofloxacin concen-
tration (0.250). Finally the last step consisted in a culture of an
aliquot of 10 m l in a medium containing 0.5 m g/ml of
ciprofloxacin. The highest level of resistance corresponded to
mutants isolated in the fourth step. One of them (Ncip) was
used for the rest of the study. Selection of mutants on solid
medium was accomplished as follows: NIMA was spread onto
TSA plates containing 0.6 m g/ml of ciprofloxacin. A survivor
(NI) was selected, cultured in liquid medium and spread again
onto TSA with 3.5 m g/ml ciprofloxacin, among survivors one
of them (NII) was cultured in TSB and spread onto TSA plates
containing 15 m g/ml and one survivor of this third step (NIII)
selected for further experiments (Table 1).
Minimal inhibitory concentration
The minimal inhibitory concentrations (MICs) were deter-
mined by the broth dilution method. Overnight cultures in
Mueller-Hinto n broth were diluted 1000-fold in fresh broth and
5 m l of the bacterial suspension (0.5 3 104 cfu/ml approxi-
mately) was inoculated in Mueller-Hinton broth containing se-
rial dilutions of the agents. MICs were determined after 18 h
of incubation at 37°C as the minimum concentrations of an-
tibiotic that inhibits visible growth.
Electrophoresis
Sodium dodecyl sulfate polyacrylam ide gel electrophoresis
(SDS-PAGE) was performed using a modification of the
method of Laemmli18 in a discontinuous system with 4M urea
added to the resolving gel.31 LPS and outer membrane protein
fractions were obtained as described elsewhere.11 To visualize
OM protein fractions, gels were stained with 0.25% Coomassie
brilliant blue,5 destained and dried, using a Bio-Rad apparatus
(miniprotean II) for electrophoresis and a gel dryer (Biorad
543). LPS gels were silver stained using a modification of the
method reported by Tsai and Frasch.33 The degree of similar-
ity between electrophoregram s was estimated by visual com-
parison of the stained gels.
Quinolone accumulation
The accumulation of quinolones was measured by a method
based on that of Mortimer and Piddock23 with some modifica-
tions. Briefly: isolates were incubated at 37°C until A600 5
0.5–0.7. Bacteria were harvested by centrifugation (9000 3 g)
at room temperature, washed, and concentrated 10-fold in phos-
phate buffer saline (PBS) pH 7.5. Quinolone was added to 1 ml
aliquots to a final concentration of 10 m g/ml. At timed inter-
vals of 30 sec, 1.5 min, 3 min, 6 min, and 12 min; samples were
centrifuged in a microfugue at 10,000 rpm at 4°C for 1 min.
Pellets were washed in 1 ml of chilled PBS at pH 7.5 and sus-
pended in 1 ml of 0.1 M glycine-HCl buffer at pH 3.0, and fi-
nally incubated at room temperature overnight to allow bacte-
rial lysis. The suspensions were centrifuged at 20°C for 25 min
to remove bacterial debris. Concentration of antibiotic in the
supernatants was determ ined fluorometrically using an SLM
Aminco 8100 spectrofluorome ter. For the efflux assay, cells
were incubated for 3 min with antibiotic before addition of the
metabolic inhibitor CCCP (carbonyl cyanide m-chlorophenyl -
hydrazone) at 100 m M of final concentration, and samples were
manipulated in the same way as for quinolone accumulation.
Specific wavelengths used to identify ciprofloxacin were 279
and 447, the extinction and emission wavelengths, respectively,
determined in 0.1 M glycine-HCl pH 3.0.
Amplification and sequencing the subunit A 
fragment QRDR of DNA gyrase using the 
polymerase chain reaction
Chromosomal DNA was prepared from each strain19 and
subjected to PCR by using two oligonucleotide primers, 5 9 -
ACGCGATGAGCGGTATTGGGT and 5 9 -TGGACATGCG-
CACTTCGGTA.12 Reactions were performed in a DNA Ther-
mal Cycler Linus FTS-1 in 0.5 mM deoxynucleotides
triphosphate, 3mM MgCl2, 1 m M of each primer, 1 U of Taq
DNA polymerase and 10 ng of bacterial DNA. Thirty cycles
were used for each reaction, with the following temperature
profiles: 94°C, 1 min; 60°C, 1 min; 72°C, 1.5 min. DNA analy-
sis by agarose gel electrophoresis (using low melting point
agarose) revealed amplification of the expected 200 bp frag-
ment in each case. PCR fragments were purified by cutting the
gel and DNA recovered by addition of 3 volumes of Nal 6M
and incubating 5 min at 55°C. Then, 7 m l of “glassmilk”  (sil-
ica gel in PBS at 0.1g/ml) were added and mixture centrifuged
and pellet washed by using a wash buffer (NacL 50Mm; Tris-
HCl pH7.5, 10Mm; EDTA 2.5 Mm in ethanol 55%); dried at
room temperature and suspended in water. Finally DNA frag-
ments were sequenced by AmpliTaq DNA-polymerase (Perkin
Elmer) using the AbiPrism® System (Perkin Elmer) at SCT,
Barcelona University.
RESULTS
Stepwise selection in vitro of a 
fluoroquinolon e-resistant mutant of 
S. marcescens
Table 1 summarizes the results of experiments of mutant se-
lection carried out on solid media. Three resistant mutants were
selected for further experim ents (NI, NII, and NIII). Table 2
shows the MICs of several antimicrobial agents. In the first step
an increase in the MIC of all antimicrobials tested was observed.
In contrast mutant NII gave susceptibility values close to those
determined in NI. Strains Ncip (isolated in liquid media) and
NIII (isolated on solid medium) gave similar antimicrobial sus-
ceptibility profiles; the susceptibility to quinolones was signif-
icantly modified in these third-step mutants.
Outer membrane protein and 
lipopolysaccharide profiles
Outer membrane proteins from NIMA and derivatives were
isolated and separated electrophoretically . Four major OMPs
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named Omp1, Omp2 and Omp3 plus OmpA of 42, 40, 39 and
37 kDa respectively, were described elsewhere. Relative pro-
portions of Omp2 and Omp3 depend upon cultural conditions
in a similar regulation to that of OmpC and OmpF of E. coli.31
Figure 1 shows the OMP profiles; Omp3 can be seen in NIMA
but was not detected in NI, NII, NIII and Ncip. Furthermore,
mutants showed a new band (about 52 kDa). No differences in
LPS electrophoretic profiles were observed (Fig. 2).
Quinolone accumulation
Results of ciprofloxacin and nalidixic acid accumulation are
shown in Figures 3 and 4, respectively. Both quinolones reached
a plateau in a few minutes. Accumulation of nalidixic acid was
identical in all strains studied. However, ciprofloxacin accu-
mulation showed a slight reduction in NI and was twofold re-
duced in NIII and Ncip (Fig. 3).
Efflux of antimicrobial agents
In the presence of carbonyl cyanide m-chlorophenylh ydra-
zone (CCCP) antibiotic accumulation by bacteria increases with
respect to energized cells.20 Addition of CCCP increased
ciprofloxacin accumulation in NI, NIII and Ncip to values sim-
ilar to that of the wild-type (Fig. 3). Similar results were ob-
tained when accumulation of acriflavine was studied (Fig. 5).
Finally accumulation of tetracycline was determined (Fig. 6).
In this case, CCCP presence produces a decrease in both efflux
and influx of tetracycline. The plot was thus unaltered, this is
in agreement with previous interpretations 1,32 suggesting that
proton motive-force inhibitors also blocked the entry of tetra-
cycline into the cell.
Identification of gyrase mutations in the 
different mutants
Figure 7 shows the sequence of the QRDR (quinolone re-
sistance determining region) of gyrA in the strains studied.
Table 3 summarizes the modifications in sequences as well as
the MIC of ciprofloxacin values. We detected only one amino
acid substitution in the conserved region (QRDR) studied in
both NIII and Ncip mutants. Thus, Serratia marcescens became
resistant to high concentrations of quinolone when there is a
cooperation between two mechanisms: (i) a single amino acid
substitution in the QRDR of gyrA, as happens in most Enter-
obacteriaceae , except E. coli;36 and (ii) low permeability (or
active extrussion) limiting the intracellular accumulation of the
drug. This is the case in NIII and Ncip in which accumulation
is limited (Fig. 3) when compared with parental strain (NIMA)
and single mutations in their QRDR region were identified
(Table 3).
DISCUSSION
It has been shown that some species of Enterobacteriac eae
such as Enterobacter cloacae and S. marcescens can acquire
resistance to quinolones at higher frequencies than E. coli.35 In
our work S. marcescens NIMA was exposed to increasing con-
centrations of quinolones both in liquid (Ncip) and on solid me-
dia (NI, NII, NIII). On solid media mutation frequencies were
high (Table 1). Cross-resistance  was detected in all mutants for
all antimicrobials but aminoglycosides  (Table 2). In principle
this result is consistent with the fact that modifications in per-
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TABLE 1. STEP W ISE SELEC TIO N O F QUINO LO N E-RES ISTA NT MU TA N TS OF S. marcescens
Number of cells Selecting Mutation
Step plated agent ( m g/mL) CFU/mL frequency a Clone
I 2.1 3 109 Cip (0.6)b 020 8 3 10 2 9 NI
II 1.8 3 109 Cip (3.5)b 117 6 3 10 2 8 NII
III 1.9 3 109 Cip (15)b. 240 1.2 3 10 2 7 NIII
aThe mutation frequencies were calculated by dividing the number of UFC/ml selected on agar plates containing the 
respective selecting agent in the concentration indicated by the number of UFC/ml plated in total.
bCiprofloxacin.
TABLE 2. MINIM A L IN HIB IT ORY CON CE NTR ATIO N ( m G/ML) OF DIFFER EN T
AN TIM ICR OBIAL AG EN TS FOR WILD-TY PE (NIMA) AND MUT ANTS
Compound NIMA NI NII NIII Ncip
Ciprofloxacin 0.06 3 5 40 30
Nalidixic acid 5 10 10 60 60
Chloramphenic ol 7 40 40 40 50
Tetracycline 14 40 40 40 30
Kanamycin 8 10 10 10 15
Erythromycin 60 70 80 80 80
Imipenem 0.125 0.25 0.5 2 2
Crystal Violet 5 5 10 10 5
Acriflavine 35 80 100 . 150 . 150
meability due to increased efflux activity do not appear to af-
fect aminoglycosides ,26 although some efflux pumps that rec-
ognize aminoglycoside s as a substrate. 4 Levels of resistance of
Ncip and NIII seemed too high to be the result of simply per-
meability modifications. In addition, only these third step mu-
tants exhibited altered susceptibility to quinolones (8-fold for
ciprofloxacin and 6-fold for nalidixic acid), whereas the sus-
ceptibility to other antibiotics remained unaltered (with respect
NI and NII) (Table 2). Then, their quinolone susceptibility
should be determined both by alterations in the target enzymes,
efflux mechanisms and eventually reduced permeability of their
outer membranes. The primary target of fluoroquinolones in
Gram-negative  bacteria is DNA gyrase, a type II topoisomerase
required for DNA replication and transcription. 14 DNA gyrase,
which is composed of two A subunits and two B subunits, is
encoded by the gyrA and gyrB genes. In these organisms, re-
sistance to fluoroquinolones is associated most frequently with
alterations in gyrA.36 The mutations are localized in an area
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FIG. 2. SDS-PAGE of lipopolysaccharid e of NIMA strain and their derivatives NI, NII, NIII, and Ncip. No significant differ-
ences were observed.
FIG. 1. SDS-PAGE of outer membrane proteins of NIMA and their derivatives NI, NII, NIII, and Ncip. Omp3 (the OmpF Ser-
ratia homolog) cannot be detected in NI, and subsequent mutants (NII and NIII) nor in Ncip. A new protein of 52 kDa appeared
concomitantly with Omp3 disparison.
designated as the quinolone resistance determining region, or
QRDR, near Tyr-122, which forms a transient covalent bond
to cleaved DNA.15 Alterations of Ser-83 result in the most ef-
fective increase in the quinolone MIC and are the most frequent
cause of quinolone resistance in mutants of E. coli selected in
vitro or isolated from patients receiving quinolone therapy.
Low-level fluoroquinolone resistance in E. coli was associated
with single mutations in the GyrA protein and high-level re-
sistance required double mutations. However, there were strains
for which high level fluoroquinolone was associated with a
gyrA QRDR sequence exhibiting a single mutation. 36 We ob-
tained similar results with NIII and Ncip strains and, in con-
trast with E. coli, mutation of Ser-83 was not required for high
level fluoroquinolone resistance in S. marcescens .
The antibacterial activity of quinolones depends on their abil-
ity to pass through the bacterial envelopes 3,29 and effective in-
hibition of the target enzymes.34,16 No differences in accumu-
lation of nalidixic acid were observed in any strain (Fig. 4). In
contrast, accumulation of ciprofloxacin was drastically reduced
in NIII and Ncip. Slight decreases in ciprofloxacin accumula-
tion were also detected in NI and NII (Fig. 3). These results
could be explained taking into account the different pathways
by which quinolones penetrate the outer membrane of bacteria.
Those with high relative hydrophobicity such as nalidixic acid,
might penetrate the outer membrane through the lipid bilayer.
If so, it should be noted that no modifications in LPS elec-
trophoretic pattern were observed in any mutant. Thus, pene-
tration of nalidixic acid should, in principle, be unaltered in the
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FIG. 4. Accumulation of nalidixic acid. r , NIMA; u , NI; n ,
NII; s , NIII; * Ncip. 
FIG. 3. Ciprofloxacin accumulation, with and without the in-
hibitor metabolic CCCP (100 m M). j , NIMA; u , NIMA-
CCCP; m , NI; n , NI-CCCP; r , NIII; *, NIII-CCCP; s , Ncip;
e , Ncip-CCCP.
FIG. 6. Tetracycline accumulation (outer concentration 20
m g/mL). CCCP (100 m M) was added after 3 min of incubation
with the antibiotic. j , NIMA; u , NIMA-CCCP; m , Ncip; s ,
Ncip-CCCP. Accumulation of tetracycline was determined flu-
orometrically at l excitatio n and l emission of 329 and 540 nm, re-
spectively, in glycine-HCl buffer pH 3.0.
FIG. 5. Acriflavine accumulation. Acriflavine (5 m g/mL) was
preloaded into cells for 3 min prior to CCCP (100 m M) addi-
tion. j , NIMA; u , NIMA-CCCP; s , Ncip; d , Ncip-CCCP.
Accumulation of acriflavine was determined fluorometrically
at l excitatio n and l em ission of 413 and 505 nm, respectively, in
glycine-HCl buffer pH 3.0.
different mutants (Fig. 2). However, MIC values of nalidixic
acid were slightly increased in mutants NI and NII, in which
mechanisms of resistance other than entry and extrusion are un-
likely to be involved. Analysis of extrusion data show that
nalidixic acid is not a good substrate for the efflux pump of
Serratia . Subsequently, blocking of extrusion mechanism only
produces a slight effect on MIC value.
Hydrophilic quinolones such as ciprofloxacin cross the outer
membrane preferentially via porins. The loss of a porin (Fig.
1) in all selected mutants could in principle affect quinolone
entry, and may lead to decreased intracellular accumulation. A
similar mechanism was described earlier.7,13,29 As can be ob-
served in Fig. 3 incubation of bacteria in the presence of CCCP
completely abolished differences in ciprofloxacin accumula-
tion. Similar results were obtained when acriflavine was used
(Fig. 5). This suggested that the wild-type bacteria pump sev-
eral drugs out. As Nikaido pointed out pathogenic and non-
pathogenic bacteria have comparable numbers of chromoso-
mally encoded multidrug resistance efflux systems, which prob-
ably have physiological roles in nature, so their role in
determining antibiotic resistance is a misfortune. Thus, it seems
they have not arisen recently in pathogens as a result of exten-
sive exposure to drugs.26 Serratia colonizes a wide variety of
habitats including fresh and polluted waters, soils and plants
where the role of efflux could be crucial to improve the phys-
iological plasticity of the genus.
We therefore propose that an energy-dependent  efflux sys-
tem in S. marcescens with a broad substrate specificity such as
lipophilic agents, tetracycline, chloramphenico l and fluoro-
quinolones, is responsible for the multidrug resistance observed
in mutants selected in vitro. It resembles the AcrAB and
MexAB efflux systems described in E. coli and P. aeruginosa
respectively. 24,25 Besides, in P. aeruginosa and Neisseria
gonorrohoeae antibiotic efflux can be linked to the overex-
pression of an OM protein of about 50 KDa.8,17 In view of these
results, the 52 KDa protein overexpressed in mutant strains may
belong to an analogous but uncharacterized efflux system  in S.
marcescens . Although the possibility of changes involving OM
proteins cannot be completely ruled out.
Phenotypic data suggested an efflux pump (giving a pattern
of antibiotic resistance similar to that of AcrAB in E. coli) in
S. marcescens . This activity could lead to the emergence of
moderately-mu ltidrug-resistant-s trains (similar to NI and NII).
However, resistance to higher concentrations of antibiotics re-
quires some additional mechanism. In the case of quinolones
and Serratia marcescens (NIII and Ncip mutants) the involve-
ment of target enzyme DNA-gyrase is required for high resis-
tance. In E. coli a single mutation in gyrA produces changes in
susceptibility; however, despite the role of other mutations in
genes like parC and others, resistance to high levels of
quinolones can be achieved only by two substitutions in the
amino acid sequence of GyrA.10 Our results showed that in Ser-
ratia , like in other enterobacteriaceae  but E. coli, a single sub-
stitution in the QRDR region is enough to produce high level
resistance, this is in agreem ent with results from other au-
thors.16,29,36 However, higher levels of quinolone resistance
were achieved when both QRDR alterations and efflux activ-
ity and/or permeability decreases act concomitantly as happen
in NIII and Ncip.
Since Serratia is recognized as a cause of hospital-acquired
infection affecting mainly the urinary tract and fluoro-
quinolones are often the antibiotics of choice to treat such in-
fections, situations similar to those described above can occur
in patients, which may lead to the emergence of clones that are
resistant to both low and high quinolone concentrations.
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TABLE 3. QRDR FRAG M EN T O F GYRA AND
TH EIR RELA TIO NSH IP TO MIC O F
CIPRO FLOXACIN IN DIFFERE NT STR AINS TEST ED
MIC Substitution aa
S. marcescens (Cip in m g/mL) in QRDR
NIMA 0.06 None
NI 3.00 None
NII 5.00 None
NIII 40.00 Ser83 to Arge83
Ncip 30.00 Asp82 to Asn82
FIG. 7. Sequence of the conserved region QRDR of the sub-
unit A of DNA gyrase of strains NIMA and their derivatives
NI, NII, NIII, and Ncip.
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